KALAMAZOO, Mich., Sept. 9 Global Pharmaceutical Services Inc. (GPSI), a provider of research and development support to the worldwide pharmaceutical and biotechnology industry announces a new clinical development bridge to India.
GPSI has entered into an exclusive partnership with Abridge Clinical Research Pvt. Ltd, a research and development company located in Mumbai, India. "We are delighted in working with such an experienced company like Abridge Clinical as their expertise and core values are very similar to those at GPSI," according to Dr. Garland A. Johnson, Senior Vice President, GPSI.
"India has become the hub of clinical research, as sponsors and Contract Research Organizations (CROs) from the USA can benefit from this relationship due to fast recruitment, good quality and cost effectiveness. In today's scenario of recession, India has become the favorite place for outsourcing the clinical studies. We are delighted to be working with GPSI in the offering of these services," as stated by Dr. Emran Khan, Director of Abridge.
This pact offers end-to-end services which include Contract Research Organization (CRO) selection for a specific clinical program, monitoring of clinical studies, auditing, quality assurance, design and conduct of Phase I - IV clinical studies (including BA/BE, PK/PD, multiple dose, food effect and steady state), faster patient enrollment, in-country sponsor representative, medical writing (including protocols, investigator brochures, statistical reports, integrated clinical reports and abstracts), data management, biostatistical services, and regulatory support. Study status updates are available in real time for all clients.
As stated in The Economic Times, (August 9, 2009), "As global pharma companies revisit their strategies by dovetailing speed, cost of drug development and tapping high growth drug markets in their business models, India is emerging as the preferred choice for clinical research services."
GPSI is the point of contact for US businesses who are interested in conducting clinical studies in India. For further information or to receive a confidential quote, please contact:
Keith B. Russell Global Pharmaceutical Services Inc. E-mail: [email protected]
Phone: 269-624-1644 Website: www.globalpharm.com
SOURCE Global Pharmaceutical Services Inc.